Unspecified skin disorder was reported in 3% of pediatric patients (2 to 15 years) receiving topiramate in a placebo-controlled (2%), adjunctive epilepsy trials
Frontiers in Pharmacoly, 11(642), 1-10
Six clinical trials involving over 900 participants established this window through systematic dose-finding studies
bereavement, violence, a disaster, low socioeconomic status, hospital admission etc.)
The established safety database for Mounjaro provides confidence in its clinical use
The post says tirzepatide is medically appropriate for adults with obesity at a BMI of 30 or higher, or overweight at a BMI of 27 or higher with weight-related comorbidities, under qualified medical supervision